Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
28720439
DOI
10.1016/j.clgc.2017.06.006
PII: S1558-7673(17)30185-4
Knihovny.cz E-zdroje
- Klíčová slova
- Pazopanib, Renal cell carcinoma, Sorafenib, Sunitinib, Survival,
- MeSH
- analýza přežití MeSH
- bevacizumab terapeutické užití MeSH
- cílená molekulární terapie MeSH
- dospělí MeSH
- fenylmočovinové sloučeniny terapeutické užití MeSH
- indazoly MeSH
- indoly terapeutické užití MeSH
- inhibitory angiogeneze terapeutické užití MeSH
- karcinom z renálních buněk farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- nádory ledvin farmakoterapie MeSH
- niacinamid analogy a deriváty terapeutické užití MeSH
- přežití bez známek nemoci MeSH
- pyrimidiny terapeutické užití MeSH
- pyrroly terapeutické užití MeSH
- registrace MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sorafenib MeSH
- sulfonamidy terapeutické užití MeSH
- sunitinib MeSH
- vaskulární endoteliální růstový faktor A antagonisté a inhibitory MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- bevacizumab MeSH
- fenylmočovinové sloučeniny MeSH
- indazoly MeSH
- indoly MeSH
- inhibitory angiogeneze MeSH
- niacinamid MeSH
- pazopanib MeSH Prohlížeč
- pyrimidiny MeSH
- pyrroly MeSH
- sorafenib MeSH
- sulfonamidy MeSH
- sunitinib MeSH
- vaskulární endoteliální růstový faktor A MeSH
- VEGFA protein, human MeSH Prohlížeč
BACKGROUND: Although targeted therapies with inhibitors of the vascular endothelial growth factor (VEGF) are the mainstay of treatment for metastatic renal cell carcinoma, there are limited data on the outcome of patients with long-term response to this treatment. PATIENTS AND METHODS: In a retrospective, registry-based study, patients continuously treated with first-line anti-VEGF agents for at least 24 months were included. In total, 219 patients had evaluable data and were included in the outcome analysis. RESULTS: Median progression-free survival (PFS) after initiation of first-line targeted therapy was 39.7 months (95% confidence interval [CI], 35.9-43.5 months), with 5-year PFS of 34.2% (95% CI, 27.2%-41.2%). Median overall survival (OS) reached 79.1 months (95% CI, 65.2-93.0 months) with the 5-year OS of 62.1% (95% CI, 54.5%-69.7%). In this cohort, 28, 103, and 88 patients achieved complete response (CR), partial response (PR), or stable disease (SD) as the best response, respectively. Median PFS and OS were comparable in patients with PR and SD, but significantly longer in patients with CR (log rank test P value for PFS difference < .001 and .009 for OS difference). CONCLUSION: There are marked differences in PFS and OS between patients who receive long-term anti-VEGF treatment, achieving CR and non-CR as the best clinical response. Patients with non-CR experienced a relatively high progression rate shortly after the landmark time point of 2 years.
Department of Oncology University Hospital Pilsen Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
University Hospital in Hradec Kralove Hradec Kralove Czech Republic
Citace poskytuje Crossref.org
